Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 2/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 11/20 | 0.44 |
| ▸ | CDK2 | P24941 | 9/20 | 0.44 |
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302493 | 0.86 | IDH2 (0.50) | IDH2MAPKAPK2CDK2SYKMAPK3 | |
| SCHEMBL3304385 | 0.86 | IDH2 (0.50) | IDH2MAPKAPK2CDK2SYKMAPK3 | |
| SCHEMBL3309511 | 0.86 | IDH2 (0.50) | IDH2MAPKAPK2CDK2SYKMAPK3 | |
| SCHEMBL3299720 | 0.85 | IDH2 (0.48) | IDH2MAPKAPK2CDK2CHEK2PRKCZ | |
| SCHEMBL3303060 | 0.85 | IDH2 (0.48) | IDH2MAPKAPK2CDK2CHEK2PRKCZ | |
| SCHEMBL3301327 | 0.85 | IDH2 (0.46) | IDH2MAPKAPK2CDK2SYKMAPK3 | |
| SCHEMBL3304781 | 0.85 | IDH2 (0.46) | IDH2MAPKAPK2CDK2SYKMAPK3 | |
| SCHEMBL3305517 | 0.84 | MAPKAPK2 (0.55) | IDH2MAPKAPK2CDK2SYKMAPK3 | |
| SCHEMBL3303949 | 0.84 | MAPKAPK2 (0.55) | IDH2MAPKAPK2CDK2SYKMAPK3 | |
| SCHEMBL3300860 | 0.84 | CDC7 (0.47) | IDH2MAPKAPK2CDK2SYKMAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | IDH2 671/4885MAPKAPK2 23/4885CDK2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.